Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 9/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803462 | 0.87 | CCR3 (0.67) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL12601592 | 0.86 | CCR3 (0.58) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL15140944 | 0.84 | CCR3 (0.73) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL69200 | 0.83 | CCR3 (0.67) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL3107807 | 0.83 | CCR3 (0.71) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL24404498 | 0.81 | CCR3 (0.69) | CCR3ACHEBCHE | |
| SCHEMBL4499901 | 0.81 | CCR3 (0.69) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL4499239 | 0.81 | CCR3 (0.69) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL1714316 | 0.81 | CCR3 (0.74) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL803083 | 0.81 | CCR3 (0.58) | CCR3ACHEBCHEALDH1A1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-16 | — | — | US | disclosed |
| US-8802720-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-08-29 | — | — | US | disclosed |
| US-8445530-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8188096-B2 | Protein kinase targeted therapeutics | NORTHWESTERN UNIVERSITY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110166153-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-7919485-B2 | Protein kinase targeted therapeutics | NORTHWESTERN UNIVERSITY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| US-20100016587-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080051410-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051410-A1 | Protein Kinase Targeted Therapeutics | NORTHWESTERN UNIVERSITY (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166153-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885ACHE 4001/4885BCHE 2311/4885 |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20130225605-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | CCR3 4418/4885ACHE 933/4885BCHE 224/4885 |
| US-20100016587-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885ACHE 4001/4885BCHE 2311/4885 |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | CCR3 1019/4885ACHE 4772/4885BCHE 4680/4885 |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | CCR3 4495/4885ACHE 4761/4885BCHE 4620/4885 |
| US-20080051410-A1 | Protein Kinase Targeted Therapeutics | MAP3K1, MAP3K6, MAPK1 | CCR3 2116/4885ACHE 4001/4885BCHE 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.